IP Library Granted Patent US 7,538,183
Granted Patent B2
US 7,538,183 · App. 11/671,095 · Granted May 26, 2009

HPV vaccine comprising peptides from host cell proteins

Assignee: University College Cardiff Consultants Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,538,183
App. No.
11/671,095
Granted
May 26, 2009
Kind
B2
Abstract

The present invention relates to a human papillomavirus (HPV) vaccine that comprises peptides from host cell proteins and more particularly, a vaccine that is directed against cancers that are associated with HPV infections, such as cervical cancer, head and neck cancer and skin cancers. The peptides comprise fragments of host cell proteins that have been targeted for degradation by HPV proteins, such as E6 and E7 and are presented on the surface of HPV infected cells in relatively large amounts. These peptides can be recognised by CTL and elicit an immune response, and are therefore ideal tumour-specific markers. The invention also relates to novel peptide: peptide complexes such as peptide/HLA complexes and their use in a tumour-specific vaccine.

Claims (6)

1. An immunogenic composition comprising: at least one isolated, purified, synthesised or recombinant peptide, wherein the peptide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:16.

2. An immunogenic composition comprising: at least one isolated, purified, synthesised or recombinant peptide selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ IDNO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:16 and, further at least one isolated, purified, synthesized or recombinant HLA molecule.

3. An isolated peptide selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:16.

4. A complex comprising: at least one peptide selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:16 in association with an HLA molecule.

5. A complex according to claim 4 , wherein the HLA molecule is HLA-A molecule.

6. A complex according to any one of claims 4 or 5 , wherein the HLA molecule is HLA-0201.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2007
From: KWUNG MAN, STEPHEN TZE
To: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
Reel/Frame 019223/0146 →
Priority Claims (1)
GB 0417430.6 · Aug 5, 2004 · national
Continuity (2)
Continuation PCTGB200500296200 · Jul 27, 2005
Related Publication 20070218074A1 · Sep 20, 2007